Amyris (AMRS) Stock Rating Lowered by ValuEngine
Amyris (NASDAQ:AMRS) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Thursday.
Several other analysts have also commented on the company. Zacks Investment Research lowered Amyris from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. B. Riley began coverage on Amyris in a research note on Thursday, January 25th. They issued a “buy” rating and a $8.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Amyris in a research note on Thursday, January 18th. Finally, Cowen reaffirmed a “hold” rating and issued a $4.00 price target on shares of Amyris in a research note on Wednesday, November 29th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $7.69.
Shares of Amyris (NASDAQ:AMRS) opened at $5.32 on Thursday. The company has a debt-to-equity ratio of -0.78, a current ratio of 0.92 and a quick ratio of 0.82. The company has a market capitalization of $226.79, a price-to-earnings ratio of -0.94 and a beta of 0.38. Amyris has a one year low of $1.86 and a one year high of $10.65.
Institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its stake in Amyris by 16.3% in the second quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 4,603 shares in the last quarter. Carl Domino Inc acquired a new position in Amyris in the third quarter worth $182,000. Creative Planning acquired a new position in Amyris in the fourth quarter worth $188,000. KBC Group NV boosted its stake in Amyris by 228.4% in the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 41,834 shares in the last quarter. Finally, Compagnie Lombard Odier SCmA boosted its stake in Amyris by 60.0% in the fourth quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 39,000 shares in the last quarter. 22.71% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.watchlistnews.com/amyris-amrs-stock-rating-lowered-by-valuengine/1905100.html.
Amyris Company Profile
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.